Veracyte Acquires Convergent Genomics, Expanding its Urology Diagnostics Portfolio with a Urinary Tumor DNA Testing Platform

manilatimes.net · 2026-09-14

Acquisition positions Veracyte to deliver powerful genomic insights from urine, tissue, and blood to help guide bladder cancer care across the patient journey

TickrTrends take: Veracyte's acquisition of Convergent Genomics adds a urinary tumor DNA testing capability to its urology diagnostics offerings, potentially broadening its addressable market within the Healthcare sector. TickrTrends currently assesses VCYT as fairly valued, so investors should monitor whether this expansion translates into revenue growth that justifies any premium to current valuation levels. The success of integrating this new platform and its commercial adoption will be key metrics to track relative to the company's valuation going forward.

Read the full story at manilatimes.net →